Is MSTR Stock Fundamentally Misunderstood?
Software firm turned Bitcoin treasury Strategy (NASDAQ:MSTR) has made waves…
Sell
50
IOBT Quote, Financials, Valuation and Earnings
Last price:
$1.50
Seasonality move
:
-7.58%
Day range:
$1.49 - $1.57
52-week range:
$0.66 - $1.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.74x
Volume:
93.5K
Avg. volume:
173.7K
1-year change:
17.19%
Market cap:
$98.8M
Revenue:
--
EPS (TTM):
-$1.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IOBT
IO Biotech
|
-- | -$0.23 | -- | -3.23% | $9.50 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.28 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IOBT
IO Biotech
|
$1.50 | $9.50 | $98.8M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.59 | $5.00 | $49.6M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.64 | $0.85 | $3.7M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.51 | -- | $24.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$4.63 | $1.00 | $3.3M | -- | $0.00 | 0% | 1.48x |
|
TOVX
Theriva Biologics
|
$0.50 | $7.00 | $4.1M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IOBT
IO Biotech
|
-- | -0.443 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.250 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.642 | -- | -- |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IOBT
IO Biotech
|
-- | -$22.6M | -- | -- | -- | -$23.1M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
IO Biotech vs. Competitors
-
Which has Higher Returns IOBT or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to IO Biotech's net margin of -11511.11%. IO Biotech's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.34 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About IOBT or ATNM?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 533.33%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 214.47%. Given that IO Biotech has higher upside potential than Actinium Pharmaceuticals, analysts believe IO Biotech is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is IOBT or ATNM More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.271, suggesting its less volatile than the S&P 500 by 127.061%.
-
Which is a Better Dividend Stock IOBT or ATNM?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or ATNM?
IO Biotech quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. IO Biotech's net income of -$22.4M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, IO Biotech's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$22.4M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns IOBT or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to IO Biotech's net margin of -49.65%. IO Biotech's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.34 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About IOBT or NBY?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 533.33%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 32.07%. Given that IO Biotech has higher upside potential than NovaBay Pharmaceuticals, analysts believe IO Biotech is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is IOBT or NBY More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock IOBT or NBY?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or NBY?
IO Biotech quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IO Biotech's net income of -$22.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IO Biotech's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$22.4M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns IOBT or NNVC?
Nanoviricides has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.34 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About IOBT or NNVC?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 533.33%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 330.46%. Given that IO Biotech has higher upside potential than Nanoviricides, analysts believe IO Biotech is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 NNVCNanoviricides0 0 0 -
Is IOBT or NNVC More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.
-
Which is a Better Dividend Stock IOBT or NNVC?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or NNVC?
IO Biotech quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. IO Biotech's net income of -$22.4M is lower than Nanoviricides's net income of -$2.2M. Notably, IO Biotech's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$22.4M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns IOBT or OGEN?
Oragenics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.34 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About IOBT or OGEN?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 533.33%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 548.01%. Given that Oragenics has higher upside potential than IO Biotech, analysts believe Oragenics is more attractive than IO Biotech.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 OGENOragenics0 1 0 -
Is IOBT or OGEN More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock IOBT or OGEN?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or OGEN?
IO Biotech quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. IO Biotech's net income of -$22.4M is lower than Oragenics's net income of -$2.2M. Notably, IO Biotech's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 1.48x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$22.4M OGENOragenics1.48x -- -- -$2.2M
-
Which has Higher Returns IOBT or TOVX?
Theriva Biologics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.34 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About IOBT or TOVX?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 533.33%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1301.12%. Given that Theriva Biologics has higher upside potential than IO Biotech, analysts believe Theriva Biologics is more attractive than IO Biotech.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 TOVXTheriva Biologics1 1 0 -
Is IOBT or TOVX More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock IOBT or TOVX?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or TOVX?
IO Biotech quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. IO Biotech's net income of -$22.4M is lower than Theriva Biologics's net income of -$4.3M. Notably, IO Biotech's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$22.4M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet or Amazon the Better Buy?
Alphabet (NASDAQ:GOOG) and Amazon (NASDAQ:AMZN) are two of the mega-cap…
Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
20
KARO alert for Jun 13
Karooooo [KARO] is down 20.19% over the past day.
Sell
18
OXM alert for Jun 13
Oxford Industries [OXM] is down 13.91% over the past day.
Sell
46
CRMT alert for Jun 13
America's Car-Mart [CRMT] is down 13.44% over the past day.
